Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
聖地亞哥,2024年5月2日(環球新聞專線)——Crinetics Pharmicals, Inc.(納斯達克股票代碼:CRNX)今天宣佈,將在美國金融市場收盤後,於2024年5月9日星期四公佈2024年第一季度財務業績。公司管理層將在美國東部時間下午 4:30 召開電話會議,討論財務業績並提供業務最新情況。
Conference Call & Webcast
電話會議和網絡直播
Thursday, May 9th @ 4:30 PM ET | |
Domestic: | 1-888-886-7786 |
International: | 1-416-764-8658 |
Conference ID: | 71864759 |
5月9日,星期四第四 @ 美國東部時間下午 4:30 | |
國內: | 1-888-886-7786 |
國際: | 1-416-764-8658 |
會議編號: | 71864759 |
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me link for instant telephone access to the event.
參與者可以使用上面的 “訪客撥入 #s” 接聽接線員的回覆,或者單擊 “給我打電話” 鏈接以即時通過電話訪問活動。
Call me:
給我打電話:
Webcast:
網絡直播:
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, first-in-class, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the Company's drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
關於 Crinetics 製藥
Crinetics Pharmaceutics是一家臨床階段的製藥公司,專注於內分泌疾病和內分泌相關腫瘤的新療法的發現、開發和商業化。Paltusotine是同類首創的口服生長抑素受體(SST2)激動劑,目前處於肢端肥大症的3期臨床開發和與神經內分泌腫瘤相關的類癌綜合徵的2期臨床開發。Crinetics 已在 CRN04894 的 1 期臨床研究中證明了藥理學概念驗證。是一種在研的、同類首創的口服 ACTH 拮抗劑,目前正處於治療先天性腎上腺增生和庫欣氏病的 2 期臨床研究中。該公司的所有候選藥物均爲口服給藥,這些新化學實體源於內部藥物發現工作,包括針對各種內分泌疾病的額外發現計劃,例如甲狀旁腺功能亢進、多囊腎病、格雷夫斯病、甲狀腺眼病、糖尿病和肥胖。
Contact:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
聯繫人:
科裏·戴維斯
LifeSci 顧問有限公司
cdavis@lifesciadvisors.com
(212) 915-2577
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
858 345-6075
媒體:
娜塔莉·巴迪羅
企業傳播主管
nbadillo@crinetics.com
858 345-6075
Source: Crinetics Pharmaceuticals, Inc.
資料來源:Crinetics 製藥公司
譯文內容由第三人軟體翻譯。